RESUMO
AIM: To compare the efficacy, safety and stability of laser in-situ keratomileusis (LASIK) Zyoptix and PlanoScan (PS) systems for the surgical correction of myopia with and without astigmatism. METHODS: In this retrospective study we analyzed the results of 198 eyes of 99 patients (randomly chosen) who underwent LASIK Zyoptix treatment and 198 eyes of 99 patients (randomly chosen) who underwent LASIK PlanoScan standard ablation treatment. Patients were followed for a period of 12 months after treatment. All surgeries were performed with the Bausch & Lomb Technolas 217z. Data on uncorrected (UCVA) and best spectacle-corrected (BSCVA) visual acuity, efficacy, predictability, stability and safety were analyzed. RESULTS: Mean preoperative spherical error in the Zyoptix group was -7.16 D (range= 0 to -16.50, SD = 3.21) and in the PS group -5.31 D (range= 0 to -16.50, SD=3.13). Mean preoperative cylinder was -1.30 D (range= -0.25 to 5.00, SD=0.99) and -1.17 D (range= -1 to -4.00, SD=0.85) respectively. Mean spherical deviation from expected at 1 year in the Zyoptix group was -0.13 D (range= -1.75 to 2, SD=0.73) and in the PS group -0.16 D (range= -4.50 to 2, SD = 0.75). Mean cylinder at 1 year was -0.69 D (range= -0.50 to 0.75, SD= -0.13) and -0.69 D (range = 0 to -2.25, SD = 0.46) respectively. At 1 year, the UCVA in the Zyoptix group was 6/12 or better, 6/7.5 or better and 6/6 or better in 87%, 60% and 27% respectively, and in the PS group 92%, 64% and 39% respectively. CONCLUSIONS: Both treatments can safely and effectively treat myopia and astigmatism with stable results up to one year. Zyoptix was found to show better outcomes in terms of safety and efficacy.
